Mar
17
2022
On demand

Flexible and scalable solutions for AAV viral vector production using a templated platform

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Adeno-associated virus (AAV) has become an increasingly popular viral vector for gene therapy. Currently, there are two approved AAV-based gene therapies, and the number of clinical trials is steadily increasing. As with most viral vector therapies, their production is labour intensive and expensive due to the use of adherent cell culture production processes. For process intensification, the industry has begun to utilize bioreactors. Here, we highlight our development of a suspension based AAV upstream production process to provide a more efficient and cost-effective bioprocessing solution for large scale production

  • How suspension adapted cell lines for transient transfection meet AAV production needs
  • The benefits of scalable solutions with simplified production processes for viral vector manufacturing
  • The importance of cell line and cell culture media compliance with GMP regulations
  • Robust process design, amendable to multiple transfections reagents and serotypes

Eva Fong

Principal Scientist, Virus and Gene Therapy Bioprocessing, Life Sciences Business Sector of Merck

Eva received her B.S. in Chemistry and Biological Sciences from the University of California, Irvine. Since graduating, she has held roles in multiple organizations conducting pre-clinical, process development, engineering, and manufacturing activities for monoclonal antibody and viral vector therapeutics. At MilliporeSigma, she leads a team responsible for all upstream and downstream scale-up R&D to develop best-in-class lentiviral and AAV manufacturing products and templates.

SPEAKERS

Eva Fong
Principal Scientist, Virus and Gene Therapy Bioprocessing at MilliporeSigma

You might also like

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
29
Days
16
Hrs
23
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
21
Days
8
Hrs
23
Min
Register

Optimizing E. Coli cell growth performance with in-line, real-time OD600...

T Buch
R Shanbaky
Tanja Buch
Tanja Buch
Technical Director at Biifactory Competence Center
Ramsey  Shanbaky
Ramsey Shanbaky
Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
1 Jun 2022
14
Days
16
Hrs
23
Min
Register

Manufacturing considerations for viral and non-viral platform selection

V Slepushkin,
A Noyes,
A Hagerman et al.
Vladimir Slepushkin
Vladimir Slepushkin
Global Head of Manufacturing at MedTherapy Biotech
Aaron Noyes
Aaron Noyes
Vice President of Development at Codiak Biosciences
Allison Hagerman
Allison Hagerman
Vice President, Product Development, Oncolytics Biotech
Laurens  Sierkstra
Laurens Sierkstra
Senior Director, Business Leader, Purification at Thermo Fisher Scientific
10 May 2022
Watch now

From cells to purified capsids: How to develop a scalable rAAV process

Å Hagner McWhirter
Åsa Hagner McWhirter
Åsa Hagner McWhirter
Principal Scientist at Cytiva
3 May 2022
Watch now